Get the Stockscreener App
1.01
0.00%
0.00
After Hours:
.97
-0.04
-3.96%
Cardiol Therapeutics Inc stock is traded at $1.01, with a volume of 124.52K.
It is up +0.00% in the last 24 hours and down -13.68% over the past month.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
See More
Previous Close:
$1.01
Open:
$1.02
24h Volume:
124.52K
Relative Volume:
0.52
Market Cap:
$85.09M
Revenue:
-
Net Income/Loss:
$-21.65M
P/E Ratio:
-3.0413
EPS:
-0.3321
Net Cash Flow:
$-15.84M
1W Performance:
+12.72%
1M Performance:
-13.68%
6M Performance:
-47.94%
1Y Performance:
-42.29%
1-Day Range:
$0.9593
$1.05
1-Week Range:
$0.8727
$1.10
52-Week Range:
$0.7709
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
Compare CRDL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.01 | 85.09M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jun-26-24 | Initiated | ROTH MKM | Buy |
| Apr-22-24 | Initiated | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc Stock (CRDL) Latest News
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Roth Capital Has Bearish Forecast for CRDL Q1 Earnings - Defense World
Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday - Defense World
Cardiol Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Earns “Buy” Rating from HC Wainwright - Defense World
Northwestern University enrols first subject in trial of drug for pericarditis - Yahoo
(CRDL) Pivots Trading Plans and Risk Controls (CRDL:CA) - news.stocktradersdaily.com
ardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics Commences Phase III Trial for CardiolRx™ in Recurrent Pericarditis - TipRanks
Cardiol Therapeutics starts phase III trial for heart drug - Investing.com Australia
Breakthrough Pericarditis Drug Enters Pivotal Phase III Trial After Phase II Success - Stock Titan
3 Reasons to Sell CSV and 1 Stock to Buy Instead - The Globe and Mail
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics Reports Increased Losses Amid Rising Expenses - TipRanks
Long Term Trading Analysis for (CRDL) (CRDL:CA) - news.stocktradersdaily.com
HC Wainwright Has Negative Outlook for CRDL FY2025 Earnings - Defense World
H.C. Wainwright maintains $9 target on Cardiol Therapeutics stock By Investing.com - Investing.com UK
Cardiol Therapeutics (NASDAQ:CRDL) Receives “Buy” Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year Low – Should You Sell? - Defense World
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate - Yahoo Finance
Cardiol Therapeutics advances heart disease treatments By Investing.com - Investing.com South Africa
Cardiol Therapeutics Inc. - menafn
Stocks In Play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics Advances Heart Disease Treatments with Promising Clinical Results - TipRanks
Cardiol Therapeutics advances heart disease treatments - Investing.com
Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile
Virtu Financial LLC Invests $61,000 in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 5% – Time to Sell? - Defense World
Atria Investments Inc Takes Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Schedules Annual General Meeting for May 2025 - TipRanks
Financial Comparison: Cardiol Therapeutics (NASDAQ:CRDL) versus Cortexyme (NASDAQ:CRTX) - Defense World
Cardiol Therapeutics to Present at TD Cowen Health Care Conference - TipRanks
Cardiol Therapeutics to present at health care conference - Proactive Investors USA
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile
Can Cardiol's Presentation at Major Healthcare Conference Signal New Clinical Developments? - Stock Titan
Cardiol Therapeutics (TSE:CRDL) Hits New 12-Month LowWhat's Next? - MarketBeat
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 - Investing News Network
Cardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Average PT from Analysts - Defense World
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Fa - Newsfile
Promising Potential of Cardiol Therapeutics’ CRD-38 Justifies Buy Rating Amidst Market Need for HFpEF Treatment - TipRanks
JACC data highlights Cardiol’s potential to differentiate in HF space - Yahoo Finance
Cardiol Therapeutics reports heart failure treatment progress By Investing.com - Investing.com Nigeria
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure - Proactive financial news
Cardiol Therapeutics reports heart failure treatment progress - Investing.com India
Cardiol Therapeutics Advances Heart Failure Treatment with New Research Publication - TipRanks
Cardiol Therapeutics Inc Stock (CRDL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):